Many treated individuals either do not respond to these therapies (innate resistance) or show recurrence or develop resistance to treatments (adaptive resistance).3,4 Patient stratification is limited to screening of PD-L1 expression for immunotherapy, and no other clinical biomarkers have been identified to differentiate responders from non-responders.5–7 Hence, there is a need to identify combinatorial therapies to the right subset of patients with CRC. Here, CD274 is linked to colorectal carcinoma.